Store at -20C

33156



For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	<b>Reactivity:</b> H Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 48-200	<b>Source/Isotype:</b> Rabbit IgG	<b>UniProt ID:</b> #P29590	Entrez-Gene Id: 5371
Product Usage Information		<b>Application</b> Western Blotting			<b>Dilution</b> 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. <i>Do not aliquot the antibody.</i>				
Specificity/Sensitivity		PML (E5R8T) Rabbit mAb recognizes endogenous levels of total PML protein.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro364 of human PML protein.				
Background		Promyelocytic leukemia protein (PML) functions via its association with PML bodies in the nucleus (1). PML bodies are dynamic protein aggregates that are interspersed between chromatin in the nuclei of most mammalian cells. The PML protein acts as a scaffold in PML bodies to recruit other proteins, a process regulated by post-translational modifications, such as sumoylation. PML bodies function to regulate a large number of cellular processes, such as tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense (1). The chromosomal translocation t(15;17)(q21;q21) involving the fusion of PML and RARalpha is found in acute promyelocytic leukemia (APL), while a second translocation t(9;15)(p13;q24) involving the fusion of PML and PAX5 was found in acute lymphoblastic leukemia (ALL) (2-6). In addition, PML is frequently inactivated or downregulated in cancer.				
Background References		1. Lallemand-Breitenbach, V. and de Thé, H. (2018) <i>Curr Opin Cell Biol</i> 52, 154-61. 2. de Thé, H. et al. (1991) <i>Cell</i> 66, 675-84. 3. Goddard, A.D. et al. (1991) <i>Science</i> 254, 1371-4. 4. Nebral, K. et al. (2007) <i>Br J Haematol</i> 139, 269-74. 5. Qiu, J.J. et al. (2011) <i>Oncogene</i> 30, 967-77. 6. Kurahashi, S. et al. (2011) <i>Oncogene</i> 30, 1822-30.				
Species Reactivity		Species reactivity is determined by testing in at least one approved application (e.g., western blot).				
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting				
Cross-Reactivity Key		H: Human Mk: Monkey				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks a more information.	are the property of t	heir respective owners.	Visit cellsignal.com	/trademarks for
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				
		approved, cleared, or purpose. Customer sh	licensed by the FDA all not use any Proc	se Only or a similar labe or other regulatory fore duct for any diagnostic o g statement. Products so	eign or domestic er or therapeutic purp	itity, for any ose, or otherwise in

Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.